Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 1 2021 | HFSA Releases Scientific Statement on the Intersection of COVID-19 and Heart Failure HFSA News Coronavirus Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More Aug 27 2021 | HFSA Announces Late Breaking Clinical Trials Coming to HFSA 2021 HFSA News Annual Scientific Meeting Read More Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 47 Page 48 Page 49 Page 50 Current page 51 Page 52 Page 53 Page 54 Page 55 … Next page Next › Last page Last »
Sep 1 2021 | HFSA Releases Scientific Statement on the Intersection of COVID-19 and Heart Failure HFSA News Coronavirus Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More
Aug 27 2021 | HFSA Announces Late Breaking Clinical Trials Coming to HFSA 2021 HFSA News Annual Scientific Meeting Read More
Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More
Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More
Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More
